Webcast: Improving Renal Outcomes in Diabetic Kidney Disease - Interpreting Recent Evidence with Novel MRAs
During this activity, experts will discuss the rationale and clinical trial data for the use of non-steroidal mineralocorticoid receptor antagonists (MRAs) in patients with diabetic kidney disease (DKD), as well as the interpretation of these data and their potential application to patient care.
This activity is part of the DKD Digital Highlights Hub.
This activity is designed for healthcare professionals, including nephrologists, cardiologists, primary care clinicians (PCPs), registered nurses and advanced practice registered nurses, pharmacists, and other allied health professionals.
After completing this activity, the participant should be better able to:
- Review the rationale and mechanisms of action of novel non-steroidal MRAs for the treatment of DKD
- Summarize and interpret the efficacy and safety of emerging non-steroidal MRAs for DKD management
George L. Bakris, MD (Chair)
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
University of Chicago Medicine
Rajiv Agarwal, MD, MS
Professor of Medicine
Indiana University School of Medicine and VA Medical Center
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.
This is an knowledged-based activity. Universal Activity Numbers (UAN): #JA4008162-9999-21-2674-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Dr. Bakris discloses the following:
Consulting Fees: Merck, Vifor, Ionis, Alynalam, Bayer, Novo Nordisk
Contracted Research: InRegen, KBP Biosciences
Dr. Agarwal discloses the following:
Salary: Indiana University, VA
Royalty: Up To Date
Consulting Fees: Akebia Therapeutics Inc; Astrazeneca AB; Astrazeneca Pharmaceuticals LP; Bayer Healthcare Pharmaceuticals Inc.; Boehringer Ingelheim B.V.; Boehringer Ingelheim International GMBH
Boehringer Ingelheim Pharma GbmH & Co KG; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Ironwood Pharmaceuticals, Inc; Janssen Research & Development, LLC; Relypsa, Inc. Sanofi Vifor Fresenius Medical Care Renal Pharma Ltd.; Merck & Co; Lexicon; Reata
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period April 7, 2021 through April 7, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.